AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04999735 — intervention group
Intervention type: BEHAVIORAL
Intervention: Withings Steel HR
Description: The Withings Steel HR is a commercially available smartwatch that combines various sensors to measure activity (steps, sleep, etc.) and heart rate (HR). HR is measured using a PPG (photoplethysmogram, i.e. optically obtained volumetric measurement) based on a commercially available sensor (AS7000) incorporating low-noise and high-sensitivity analogue circuitry. The manufacturer supplies the algorithm for converting the PPG signal into HR values. Data is transferred from the watch to the smartphone using the Withings Health Mate app from where it will be uploaded to the output server.
Study NCT04999735 — intervention group
Intervention type: BEHAVIORAL
Intervention: Withings Body+ scale
Description: Body composition (weight, BMI and Skeletal Muscle Mass) can be assessed with the Withings Body+ smart scale at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging.
Study NCT00190671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
Study NCT01620684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metyrapone
Description: Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)
Study NCT01620684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules
Study NCT02240446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 2mA stimulation for 20 minutes twice a day for five consecutive days
Study NCT02240446 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: 2mA for 30 seconds twice a day for five consecutive days
Study NCT02633267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocational Services as usual plus Cognitive Behavioral Therapy (CBT)
Description: Teaches thought restructuring and exposure therapy to socially anxious job seekers delivered by vocational service professionals
Study NCT02633267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Vocational Services
Description: Vocational services delivered by vocational professionals at vocational service center (e.g., resume assistance, job leads)
Study NCT02633267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Vocational Services
Description: Vocational services delivered by vocational professionals at vocational service center (e.g., resume assistance, job leads)
Study NCT02990949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of trigger
Study NCT00697489 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: correction of POP plus preventive continence procedure
Study NCT00697489 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: POP surgery followed by eventual incontinence procedure
Study NCT01598259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: po 1 hour before bedtime
Study NCT01546805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Supplement
Description: The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
Study NCT01546805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
Study NCT02066142 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D mammography (Tomosynthesis)
Description: Tomosynthesis will be used as normally employed in clinical practice
Study NCT02066142 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Study NCT01646762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV
Study NCT01646762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01478477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid supplement
Description: 6 capsules per day (4.3 g)x 6 months
Study NCT01598259 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: po, 1 hour before bed
Study NCT01824485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: viscosupplementation 1+1+1
Description: intra-articular injection with 1 ampoule per week for 3 weeks
Study NCT01824485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: viscosupplementation 3 at once
Description: single intra-articular injection with 3 ampoules
Study NCT00503542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl for definitively diagnosed vaginal trichomoniasis
Description: Metronidazole 2 gms po x 1
Study NCT00503542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flagyl for definitively diagnosed vaginal trichomoniasis
Description: Metronidazole 2 gms po x 1
Study NCT00503542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Empiric Management
Description: In this arm of the study women are treated for vaginal complaints purely on the basis of their symptoms.
Study NCT04507620 — intervention group
Intervention type: DEVICE
Intervention: cervical neck collar
Description: devices used for cervical immobilization
Study NCT02193815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF06263276
Description: 4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
Study NCT02193815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Active ingredient-free vehicle to 4% solution
Study NCT00943358 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59 H1N1 vaccine
Description: 3.75-7.5ug dose
Study NCT00943358 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plain H1N1 vaccine
Description: 7.5-15ug
Study NCT01478477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
Study NCT04999735 — intervention group
Intervention type: BEHAVIORAL
Intervention: Withings Blood Pressure Monitor
Description: Blood pressure can be assessed with the automated Withings Blood Pressure Monitor at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging
Study NCT01478477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
Study NCT01478477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessments
Description: All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.
Study NCT01478477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clinical assessments
Description: All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.
Study NCT01478477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of therapy complications
Description: Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
Study NCT01478477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of therapy complications
Description: Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
Study NCT01478477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.
Study NCT01478477 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.
Study NCT01478477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Correlative/special studies
Description: Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.
Study NCT01478477 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Correlative/special studies
Description: Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.
Study NCT03606512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF
Description: Ad26.RSV.preF will be administered as IM injection at a dose of 2.5\*10\^10 vp.
Study NCT03606512 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as IM injection of sterile 0.9 percent (%) saline for injection.
Study NCT03606512 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nimenrix
Description: Nimenrix will be administered as 0.5 milliliter (mL) solution for IM injection.
Study NCT04905758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platform switching
Description: reduced implant abutment interface
Study NCT04905758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platform amtching
Description: matched implant abutment interface
Study NCT00529672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: crossectomy and short stripping
Description: under spinal or complete anaesthesia
Study NCT00529672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided sclerotherapy with foam
Description: 1 part 3% polidocanol mixed with 3 parts of air. Between 3cc - 12 cc per varicose vein>
Study NCT00529672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endovenous laser therapy
Description: 940 nm Diode laser. About 70 J/cm will be administered. Disposables from Angiocare (registered) will be used.
Study NCT03005340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: Bazedoxifene 20 mg
Study NCT02193815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2%Tofacitinib Ointment
Description: Daily Dosage: approximately 4 mg tofacitinib
Study NCT02193815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Active ingredient-free vehicle to 2% Ointment
Study NCT03126357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: FT21018 an electronic tobacco vapor product
Study NCT03126357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 4mg nicotine gum
Study NCT02193815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivonex
Description: Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
Study NCT02193815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivonex Ointment
Description: Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
Study NCT01301508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 ointment, 2%
Description: AN2728 ointment, 2%, applied twice daily for 6 weeks
Study NCT01301508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2898 ointment, 1%
Description: AN2898 ointment, 1%, applied twice daily for 6 weeks
Study NCT01301508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2898 ointment vehicle
Description: AN2898 ointment vehicle applied twice daily for 6 weeks
Study NCT01301508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 ointment vehicle
Description: AN2728 ointment vehicle applied twice daily for 6 weeks
Study NCT03436914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: After the diagnosis of NERD through patient's symptom and endoscopy, PPI (esomezol) will be given for 8 weeks. The effect of PPI for NERD patients will be analyzed.
Study NCT00934427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% nitroglycerin in TAM cream
Description: 0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures
Study NCT00934427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle cream
Description: 0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
Study NCT02425007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Study NCT00939224 — intervention group
Intervention type: DEVICE
Intervention: Model 7600 Regional Oximeter System
Description: Non-invasive regional oxygen saturation measurements
Study NCT01721031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DPNB
Description: Patients receive DPNB 30min before extubation at the end of operation
Study NCT01721031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
Study NCT04204759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Non-invasive stimulation will be conducted using a tDCS device (StarStim, Neuroelectrics, Spain).
Study NCT04204759 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
Study NCT02476357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic scalpel
Study NCT04619264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papacarie
Description: First, tooth was cleaned with a wet cotton pellet. The gel was inserted using disposable syringe tip into the cavity and its color changed from clear to cloudy indicating the presence of infected tissues. After 40 seconds, the softened carious tissue was removed using excavator by gentle pressure. The remaining gel was removed with a cotton pellet. The procedure was repeated until there was no change in the gel color indicating that there was no more infected tissue.
Study NCT04619264 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Treatment
Description: The tooth was cleaned with a wet cotton pellet to remove debris and plaque and then isolated with cotton rolls to promote a dry environment. Caries was removed using a sharp excavator and the cavity was cleaned using a small wet cotton pellet and dried with a dry cotton pellet.
Study NCT03225716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulocuplumab
Description: Ulocuplumab is a type of protein called an antibody that attacks CXCR4
Study NCT03225716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
Study NCT03005340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C
Description: Cholecalciferol granule 10 mg
Study NCT02559154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Study NCT02559154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT02559154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02559154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02559154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT02559154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02559154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT02559154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02559154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxsnteone
Study NCT02559154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxsnteone
Study NCT02559154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Study NCT02559154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study NCT03005340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment BC
Description: Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
Study NCT04382443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: At the moment of BMS implantation intervention will mean that this group will receive colchicine as described.
Study NCT01474967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
Study NCT01474967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
Study NCT04317144 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based follow-up programme.
Description: Participants who are randomized to the intervention-group will have access to web-based follow-up for one year. The programme includes short films of equipment used in intensive care e.g. ventilator, suction-device. Continous renal replacement therapy , central vein catheter among other things. About 15 short films with icu-staff talking and show how the equipment works and alarm sounds. The intervention also includes lectures about how the ICU works and what problems a critically ill patient can suffer from post-icu. There is a built-in conversation tool in the programme that can be used both by the participant and the staff who works with the follow-up programme. Questionnaires is sent out 2,6 and 12 month post-icu. The questions include PTSD, Depression, QoL and physical activity. At the end of the study, participants are sent a questionnaire asking for their experience using the web-based follow up programme.
Study NCT04317144 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No follow-up
Description: Participants randomized to no follow-up receive e-questionnaires 2, 6 and 12 months post-ICU care. The questions are the same as in web-based follow-up intervention group and include PTSD, Depression, QoL and physical activity.
Study NCT03300206 — intervention group
Intervention type: DEVICE
Intervention: Breast Biopsy
Description: A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
Study NCT01334918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: Administered by intravenous bolus.
Study NCT02628678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: FOS
Study NCT01334918 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: technetium Tc99m sestamibi /technetium Tc99m tetrafosmin
Description: Administered by intravenous infusion
Study NCT00194896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
Study NCT00194896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyburide
Description: Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
Study NCT02209415 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up
Description: Outpatient clinic visits
Study NCT01832675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocain, cutaneous spray, solution
Description: 10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.